trending Market Intelligence /marketintelligence/en/news-insights/trending/x52XAL146lYbdysUlvehHg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sucampo upsizes note offering to $260M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sucampo upsizes note offering to $260M

Sucampo Pharmaceuticals Inc. priced and upsized a previously announced debt offering to repay an existing senior secured credit facility.

The company will issue $260 million worth of 3.25% senior notes due 2021, complete with an option to purchase an additional $40 million worth of the debt.

Interest will be payable semiannually starting June 15, 2017. The notes will also convert into class A Sucampo shares at an initial conversion rate of $16.59 per share.

Sucampo initially planned on issuing $225 million of the debt.

Sucampo Pharmaceuticals secured a $250 million credit facility in October 2015 to fund its planned purchase of R-Tech Ueno. The new debt issue could help free up some of the company's cash, given that Sucampo is required to maintain at least $25 million in a restricted cash account until at least $35 million of the facility is repaid or prepaid.

Leerink Partners LLC is the sole book-running manager of the issue. The sale is expected to close Dec. 27.